Drug Profile
Research programme: ZFP-based therapeutics - Genentech/Sangamo Therapeutics
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Genentech
- Developer Genentech; Sangamo Therapeutics
- Class Proteins; Transcription factors
- Mechanism of Action DNA binding protein modulators; Genetic transcription modulators; Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (Parenteral)
- 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
- 04 Mar 2011 Preclinical development is ongoing in USA